Hemay 020

Drug Profile

Hemay 020

Alternative Names: Hemay020

Latest Information Update: 08 Oct 2015

Price : $50

At a glance

  • Originator Hainan General Sanyang Pharmaceutical; Tianjin Hemay Biotech
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease) in China (PO)
  • 01 Aug 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO)
  • 19 Jun 2015 Tianjin Hemay Pharmaceutical and Hainan General Sanyang Pharmaceutical plan a phase I trial for Solid tumours and Non small cell lung cancer in China (NCT02467569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top